HSA

Dusan M Lazic, Vladimir M Jovanovic, Jelena Karanovic, Dusanka Savic-Pavicevic, Bogdan Jovanovic

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Oleic Acid Levels in HSAInternational journal of molecular sciences · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dusan M LazicCenter for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Studentski Trg 16, 11000 Belgrade, Serbia.ORCID 0009-0006-0350-3246

Vladimir M JovanovicDepartment of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 1-3, 14195 Berlin, Germany.ORCID 0000-0002-8056-5065

Jelena KaranovicGene Regulation in Cancer Group, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444A, 11042 Belgrade, Serbia.ORCID 0000-0002-6291-5527

Dusanka Savic-PavicevicCenter for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Studentski Trg 16, 11000 Belgrade, Serbia.ORCID 0000-0002-2079-4077

Bogdan JovanovicCenter for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Studentski Trg 16, 11000 Belgrade, Serbia.ORCID 0000-0001-8613-797X

Funding

Science Fund of the Republic of Serbia #7754217, READ-DM1

6 · The paper itself

Abstract

Myotonic dystrophy type 1 (DM1) is a progressive multisystemic disease caused by a CTG repeat expansion in the

Indexed as

Muscle WeaknessMyotonic DystrophyProteostasisAnimalsDisease Models, AnimalGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksMiceMuscle, SkeletalTranscriptomeautophagyER-associated degradationHSALRmitophagymyotonic dystrophy type 1protein homeostasisproteostasisrepeat expansionsubiquitin-proteasome systemWGCNA

Identifiers

PMID41226829

DOI10.3390/ijms262110793

PMCPMC12608036

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.